Rivaroxaban is a new oral anticoagulant used in adult patients with non valvular atrial fibrillation (except atrial fibrillation caused by rheumatic heart valve disease and atrial fibrillation after heart valve replacement) to reduce the risk of stroke and systemic embolism.